## VCYT: Veracyte, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($39.49)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Veracyte, Inc. $VCYT Shares Sold by Nikko Asset Management Americas Inc.**
- Source: MarketBeat | 20251214T110936 | Somewhat-Bullish | Relevance: 100%
- Nikko Asset Management Americas Inc. decreased its holdings in Veracyte, Inc. (NASDAQ:VCYT) by 27.2% during the second quarter, selling over 614,000 shares. Other institutional investors also adjusted their stakes in the biotechnology company. Veracyte recently reported strong quarterly earnings, beating analyst estimates, and has received a "Moderate Buy" consensus rating from Wall Street analysts.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $48 | $40 | +20% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.05M) |
| Sells | 24 ($4.46M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 16.5% (+68.9%)
- Vanguard Group Inc: 10.8% (+5.0%)
- Artisan Partners Lim: 9.3% (+16.6%)
- FMR, LLC: 8.6% (-16.2%)
- ARK Investment Manag: 5.7% (+17.5%)

### Key Risks

1. High beta (1.83) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $4.5M in recent transactions.
3. Elevated short interest (8.1%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.2x), low leverage (D/E 0.09). Analyst sentiment positive (1 raises, avg +20%). Insider selling cluster ($4.5M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.4B |
| Beta | 1.83 |
| 52W Range | $22.61 - $50.71 |
| Short Interest | 8.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 27.1 |
| Current P/E | 26.5 |
| YoY Growth | -2.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -6.5% to -0.7% (+5.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.7pp (needs >3.0% for momentum thesis). MRS_5 turning positive (2.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.36x) but short-term weakness (below SMA20). MACD histogram bearish (-0.68), momentum weakening. RSI neutral at 52. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.72% (CS: 20) | Neutral |
| RSI_14 | 52.0 | Neutral |
| MACD Histogram | -0.68 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 1.087x | Above |
| vs SMA200 | 1.358x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $43.53
- **Stop Loss:** $39.49 (9.3% risk)
- **Target:** $47.57 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 297
- **Position Value:** $12,928.41
- **Portfolio %:** 12.93%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-24 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.32 | $0.51 | +59.5% |
| 2025Q2 | $0.30 | $0.44 | +48.5% |
| 2025Q1 | $0.20 | $0.31 | +51.3% |
| 2024Q4 | $0.26 | $0.36 | +40.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*